Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma

被引:12
|
作者
Alfaifi, Abdullah [1 ,2 ]
Refai, Mohammed Y. [3 ]
Alsaadi, Mohammed [1 ,4 ]
Bahashwan, Salem [4 ,5 ,6 ]
Malhan, Hafiz [7 ]
Al-Kahiry, Waiel [7 ]
Dammag, Enas [7 ]
Ageel, Ageel [7 ]
Mahzary, Amjed [8 ]
Albiheyri, Raed [1 ]
Almehdar, Hussein [1 ]
Qadri, Ishtiaq [1 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia
[2] Minist Hlth, Fayfa Gen Hosp, Jazan 83581, Saudi Arabia
[3] Univ Jeddah, Coll Sci, Dept Biochem, Jeddah 21493, Saudi Arabia
[4] King Abdulaziz Univ, King Fahad Med Res Ctr, Hematol Res Unit, Jeddah 21589, Saudi Arabia
[5] King Abdulaziz Univ, Fac Med, Dept Hematol, Jeddah 21589, Saudi Arabia
[6] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Jeddah 21589, Saudi Arabia
[7] Minist Hlth, Prince Mohammed Bin Nasser Hosp, Jazan 82943, Saudi Arabia
[8] Minist Hlth, Eradah Hosp, Jazan 82943, Saudi Arabia
关键词
metabolomics; B-cell non-Hodgkin's lymphoma; biomarkers; metabolites; early diagnosis; therapeutic; GENOMIC URACIL; LARGE-SCALE; METABOLISM; SERUM; INHIBITION; MUTATIONS; EXPRESSION; LEUKEMIA; SURVIVAL; CHROMATOGRAPHY;
D O I
10.3390/diagnostics13050861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin's lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin's lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called "metabolomics." A patient's phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin's lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin's lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin's lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    Postema, EJ
    Boerman, OC
    Oyen, WJG
    Raemaekers, JMM
    Corstens, FHM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) : 1725 - 1735
  • [2] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    Bodet-Milin, Caroline
    Ferrer, Ludovic
    Pallardy, Amandine
    Eugene, Thomas
    Rauscher, Aurore
    Faivre-Chauvet, Alain
    Barbet, Jacques
    Kraeber-Bodere, Francoise
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [3] Radioimmunotherapy: A new treatment modality for B-cell non-Hodgkin's lymphoma
    Ghobrial, Irene
    Witzig, Thomas
    ONCOLOGY-NEW YORK, 2004, 18 (05): : 623 - 630
  • [4] B-cell non-Hodgkin's lymphoma of small lymphocytes
    Novosad, O.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S22
  • [5] Thymic B-cell non-Hodgkin's lymphoma in a child
    Azuma, E
    Nishihara, H
    Qi, J
    Nagai, M
    Hiratake, S
    Zhang, XL
    Komada, Y
    Hamazaki, M
    Sakurai, M
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 57 (01) : 48 - 50
  • [6] Emerging drugs in B-cell non-Hodgkin's lymphoma
    Kassam, Shireen
    Montoto, Silvia
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (02) : 323 - 343
  • [7] Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Wang, Michael
    Zhou, Yuhong
    Zhang, Liong
    Nguyen, C. Ann
    Romaguera, Jorge
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) : 983 - 991
  • [8] RADIOIMMUNOTHERAPY IN THE PATIENT WITH B-CELL NON-HODGKIN'S LYMPHOMA
    Fernandez Natalia, Garcia
    Cuellar Angeles, Flores
    Santiago Maria del Rosario, Mora
    Perez Cristina, Gonzalez
    ATENCION FARMACEUTICA, 2012, 14 (01): : 34 - +
  • [9] HCV and HGV in B-cell non-Hodgkin's lymphoma
    Ellenrieder, V
    Weidenbach, H
    Frickhofen, N
    Michel, D
    Prümmer, O
    Klatt, S
    Bernas, O
    Mertens, T
    Adler, G
    Beckh, K
    JOURNAL OF HEPATOLOGY, 1998, 28 (01) : 34 - 39
  • [10] Antibody therapy of non-Hodgkin's B-cell lymphoma
    Paul Chinn
    Gary Braslawsky
    Christine White
    Nabil Hanna
    Cancer Immunology, Immunotherapy, 2003, 52 : 257 - 280